Tasly Pharmaceutical Group Co., Ltd. (600535.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 13.95

From 52W high−9.96%

Volume10.45M

Market capCNY 22.14B

P/E (TTM)20.0x

P/S (TTM)2.5x

Div yield2.24%

Key dataSep 18, 2026

Open

CNY 13.95

From 52W high

−9.96%

Volume

10.45M

Market cap

CNY 22.14B

ValuationView details →

P/E (Fwd)

10.0x

EV/EBITDA

11.7x

P/E (TTM)

20.0x

RSI (14)

26.5

MomentumView details →

1D Return

−1.00%

YTD Return

−8.03%

ValuationView details →

P/E (Fwd)

10.0x

P/E (TTM)

20.0x

EV/EBITDA

11.7x

EV/Sales

2.6x

P/S (TTM)

2.5x

P/B (TTM)

1.7x

ProfitabilityView details →

Gross Margin

68.04%

Net Margin

13.91%

EBITDA Margin

21.80%

ROE (TTM)

9.09%

ROA (TTM)

7.40%

Asset Turnover

0.54x

GrowthView details →

Revenue YoY

−1.86%

EPS YoY

+19.75%

FCF YoY

+45.27%

Revenue CAGR 3Y

−1.57%

EPS CAGR 3Y

+1.38%

EBITDA YoY

—

MomentumView details →

1D Return

−1.00%

YTD Return

−8.03%

1Y Return

−11.32%

RSI (14)

26.5

vs 50D SMA

−8.36%

vs 200D SMA

−5.88%

Capital & dividendView details →

Debt/Equity

0.08x

Current Ratio

3.72x

Quick Ratio

3.09x

Div Yield

2.24%

Div Rate

CNY 0.31

Div Growth 1Y

−37.88%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.23

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

8.35B

Net Income (TTM)

1.16B

Op. CF (TTM)

2.25B

Next earningsOct 26, 2026 →

Latest newsMore news →

Tasly's net profit attributable to shareholders increased by 15.23% in the first half of 2026 despite a slight revenue decline, with 10 products newly included in the 2026 National Essential Medicines List.20d ago

Tasly Pharmaceutical Group announced that 10 of its products, including two exclusive products Jinghua Weikang Jiaowan and Shaoma Zhijing Granules, were newly included in the 2026 National Essential Medicines List.30d ago

Similar companies

济川药业600566.SH Aprogen Biologics Inc.003060.KS Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited00874.HK 哈药股份600664.SH The United Laboratories International Holdings Limited03933.HK 华海药业600521.SH Find similar companies →

Latest newsMore news →

Tasly's net profit attributable to shareholders increased by 15.23% in the first half of 2026 despite a slight revenue decline, with 10 products newly included in the 2026 National Essential Medicines List.20d ago Tasly Pharmaceutical Group announced that 10 of its products, including two exclusive products Jinghua Weikang Jiaowan and Shaoma Zhijing Granules, were newly included in the 2026 National Essential Medicines List.30d ago Tasly Pharmaceutical Group reported first-half revenue of 4.20 billion RMB and net profit of 892.7 million RMB.30d ago